Stock Scorecard



Stock Summary for Abeona Therapeutics Inc (ABEO) - $6.65 as of 7/25/2025 1:30:11 PM EST

Total Score

10 out of 30

Safety Score

25 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ABEO

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ABEO

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ABEO

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ABEO

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ABEO (25 out of 100)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 6
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for ABEO

Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA 7/15/2025 12:28:00 PM
ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area - Abeona Therapeutics ( NASDAQ:ABEO ) 7/15/2025 11:30:00 AM
ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area 7/15/2025 11:30:00 AM
Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A ( MPS IIIA ) 7/11/2025 8:30:00 PM
Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million 7/2/2025 11:30:00 AM
Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy 7/1/2025 11:30:00 AM
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) 7/1/2025 11:15:00 AM
Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index 6/30/2025 11:30:00 AM
Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa 6/24/2025 11:30:00 AM
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Abeona Therapeutics ( NASDAQ:ABEO ) 6/2/2025 11:30:00 AM

Financial Details for ABEO

Company Overview

Ticker ABEO
Company Name Abeona Therapeutics Inc
Country USA
Description Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for rare, life-threatening genetic diseases. The company is headquartered in New York, New York.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 3/31/2025
Next Earnings Date 8/18/2025

Stock Price History

Last Day Price 6.65
Price 4 Years Ago 8.43
Last Day Price Updated 7/25/2025 1:30:11 PM EST
Last Day Volume 527,282
Average Daily Volume 992,791
52-Week High 7.32
52-Week Low 3.93
Last Price to 52 Week Low 69.21%

Valuation Measures

Trailing PE N/A
Industry PE 21.96
Sector PE 41.43
5-Year Average PE -6.02
Free Cash Flow Ratio 21.45
Industry Free Cash Flow Ratio 17.72
Sector Free Cash Flow Ratio 32.93
Current Ratio Most Recent Quarter 4.90
Total Cash Per Share 0.31
Book Value Per Share Most Recent Quarter 0.85
Price to Book Ratio 8.29
Industry Price to Book Ratio 33.70
Sector Price to Book Ratio 30.75
Price to Sales Ratio Twelve Trailing Months 37.76
Industry Price to Sales Ratio Twelve Trailing Months 136.89
Sector Price to Sales Ratio Twelve Trailing Months 40.01
Analyst Buy Ratings 5
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 51,157,000
Market Capitalization 340,194,050
Institutional Ownership 63.55%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 3.82%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -17.62%
Reported EPS 12 Trailing Months -0.63
Reported EPS Past Year -0.24
Reported EPS Prior Year -1.60
Net Income Twelve Trailing Months -44,185,000
Net Income Past Year -63,734,000
Net Income Prior Year -54,188,000
Quarterly Revenue Growth YOY -100.00%
5-Year Revenue Growth 11.44%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet

Total Cash Most Recent Quarter 15,936,000
Total Cash Past Year 23,357,000
Total Cash Prior Year 14,473,000
Net Cash Position Most Recent Quarter 4,798,000
Net Cash Position Past Year 10,320,000
Long Term Debt Past Year 13,037,000
Long Term Debt Prior Year 1,758,000
Total Debt Most Recent Quarter 11,138,000
Equity to Debt Ratio Past Year 0.77
Equity to Debt Ratio Most Recent Quarter 0.79
Total Stockholder Equity Past Year 44,031,000
Total Stockholder Equity Prior Year 14,826,000
Total Stockholder Equity Most Recent Quarter 41,396,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -63,001,000
Free Cash Flow Per Share Twelve Trailing Months -1.23
Free Cash Flow Past Year -58,461,000
Free Cash Flow Prior Year -37,340,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.17
MACD Signal 0.07
20-Day Bollinger Lower Band 4.36
20-Day Bollinger Middle Band 5.74
20-Day Bollinger Upper Band 7.11
Beta 1.51
RSI 63.36
50-Day SMA 5.76
150-Day SMA 4.75
200-Day SMA 5.95

System

Modified 7/24/2025 4:18:31 PM EST